Prognostic significance of a component of the Hippo pathway, TAZ, in human uterine endometrioid adenocarcinoma

Zhan,Maosheng; Ikeda,Jun‑Ichiro; Wada,Naoki; Hori,Yumiko; Nojima,Satoshi; Tahara,Shin‑Ichiro; Ueda,Yutaka; Yoshino,Kiyoshi; Kimura,Tadashi; Morii,Eiichi

doi:10.3892/ol.2016.4483

Prognostic significance of a component of the Hippo pathway, TAZ, in human uterine endometrioid adenocarcinoma

Authors:
- Maosheng Zhan
- Jun‑Ichiro Ikeda
- Naoki Wada
- Yumiko Hori
- Satoshi Nojima
- Shin‑Ichiro Tahara
- Yutaka Ueda
- Kiyoshi Yoshino
- Tadashi Kimura
- Eiichi Morii
View Affiliations

Affiliations: Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan
Published online on: April 20, 2016 https://doi.org/10.3892/ol.2016.4483
Pages: 3611-3616
Copyright: © Zhan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transcriptional coactivator with PDZ‑binding motif (TAZ) is a crucial component of the Hippo tumor suppressor pathway, interacting with transcriptional factors to regulate cell proliferation, apoptosis and tumorigenesis. TAZ and its paralog, Yes‑associated protein (YAP), are activated at high frequencies during the progression towards malignancy in various tumors. Recently, YAP has been identified to modulate oncogenic features in endometrial adenocarcinoma, and it has also been reported that the nuclear expression of YAP is correlated with the poorly‑differentiated form of endometrioid adenocarcinoma. In contrast to YAP, no studies have investigated TAZ expression in endometrioid adenocarcinoma. In the present study, TAZ expression was immunohistochemically examined in 55 clinical samples of endometrioid adenocarcinoma, and the clinical implications were evaluated. The results demonstrated that TAZ was located primarily in the cell nuclei, and that high TAZ expression was significantly correlated with high tumor‑factor (P=0.024), stage (P=0.041) and histological grade (P=0.001), lymph node metastasis (P=0.046), recurrence (P=0.002) and a poor prognosis (P=0.007). Furthermore, univariate analysis identified that high TAZ expression was a poor prognostic factor for overall and disease‑free survival. To the best of our knowledge, the present case is the first to report the clinical implications of TAZ in endometrioid adenocarcinoma of the uterus. TAZ may become a marker of a poor prognosis in endometrioid adenocarcinoma.

View Figures

View References

1	Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC and Yaffe MB: TAZ: A novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI
2	Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL: TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008. View Article : Google Scholar : PubMed/NCBI
3	Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
4	Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008. View Article : Google Scholar : PubMed/NCBI
5	Chow A, Hao Y and Yang X: Molecular characterization of human homologs of yeast MOB1. Int J Cancer. 126:2079–2089. 2010.PubMed/NCBI
6	Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 8:e655392013. View Article : Google Scholar : PubMed/NCBI
8	Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al: Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 17:2130–2139. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125:1253–1267. 2006. View Article : Google Scholar : PubMed/NCBI
10	Muramatsu T, Imoto I, Matsui T, Kozaki K, Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Dong Q, Zhang Q, Li Z, Wang E and Qiu X: Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Su L and Ou Q: Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer. 48:1227–1234. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q and Hong W: A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 68:2592–2598. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS and Yang X: TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 30:2181–2186. 2011. View Article : Google Scholar : PubMed/NCBI
15	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
16	Horn LC, Meinel A, Handzel R and Einenkel J: Histopathology of endometrial hyperplasia and endometrial carcinoma: An update. Ann Diagn Pathol. 11:297–311. 2007. View Article : Google Scholar : PubMed/NCBI
17	Mamat S, Ikeda J, Enomoto T, Ueda Y, Rahadiani N, Tian T, Wang Y, Qiu Y, Kimura T, Aozasa K and Morii E: Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep. 23:1221–1227. 2010.PubMed/NCBI
18	Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, Ueda Y, Umehara R, Tian T, Wang Y, Enomoto T, Kimura T, et al: Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 102:903–908. 2011. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Ikeda JI, Rahadiani N, Mamat S, Ueda Y, Tian T, Enomoto T, Kimura T, Aozasa K and Morii E: Prognostic significance of elongator protein 3 expression in endometrioid adenocarcinoma. Oncol Lett. 3:25–29. 2012.PubMed/NCBI
20	Tsujiura M, Mazack V, Sudol M, Kaspar HG, Nash J, Carey DJ and Gogoi R: Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One. 9:e1009742014. View Article : Google Scholar : PubMed/NCBI
21	Zaino RJ: FIGO staging of endometrial adenocarcinoma: A critical review and proposal. Int J Gynecol Pathol. 28:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
23	Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J and Zider A: SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol. 18:435–441. 2008. View Article : Google Scholar : PubMed/NCBI